BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Money on the Move: a March Fundraising Bonanza

  Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.

  March 9, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Business

  Sanofi and SOBI Hit Phase III Endpoint in Severe Hemophilia A

  The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.

  March 9, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  BioNTech and Regeneron Turn Attention to NSCLC in Partnership Expansion

  BioNTech announced an expansion on its collaboration with Regeneron to continue advancing mRNA technology and develop novel treatments for a variety of cancers.

  March 9, 2022

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Business

  Genomics is Only the First Step in Developing Effective Cancer Treatments

  Before next-generation metabolomics becomes mainstream, the medical establishment needs to expand its mindset around cancer and translate this understanding into the clinic.

  March 9, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Biopharma Companies Line Up Presentations Ahead of AACR Oncology Conference

  Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.

  March 9, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Policy

  Settlement Opens Doors for Biosimilars of Abbvie’s Most Profitable Drug

  AbbVie and Alvotech have settled a case, granting Alvotech a non-exclusive license to all Humira-related patents in the United States beginning on July 1, 2023.

  March 9, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Biotech Bay

  Popular Multiomics Tech Innovator Nets $200M to Expand Platform Adoption

  DNAnexus announced it has secured $200 million in funding to advance the life sciences industry’s adoption of its platform.

  March 9, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Adaptive Aligns Behind Two Key Business Areas, Cuts 12% of Staff

  Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.

  March 9, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: Orbit and WuXi Link on Peptides, Immunovia, OSE and More

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  March 9, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Sets Review Date for Acadia’s Alzheimer’s Psychosis Candidate

  This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.

  March 9, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh